1 / 4

acute upper respiratory infections (auri) therapeutics - pip

The AURI Market is Estimated to Show Slow Growth at a 1.3% Compound Annual Growth Rate from 2009 to 2017.

guest17519
Télécharger la présentation

acute upper respiratory infections (auri) therapeutics - pip

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acute Upper Respiratory Infections (AURI) Therapeutics -Pipeline Assessment and Market Forecasts to 2017

  2. The AURI Market is Estimated to Show Slow Growth at a 1.3% Compound Annual Growth Rate from 2009 to 2017. The global Acute Upper Respiratory Infection (AURI) market was valued at $692m in 2010 and is forecast to show slow growth at a compound annual growth rate (CAGR) of 1.3% to reach $755m by 2017. The growth will primarily be driven by an increase in the general population and depleting environmental conditions, which can increase the incidence of the disease. At present, the market has a lot of approved therapies (many of them with generics) and a lot of off-label drugs in the market. Strong Market Includes Therapies that have Increased the AURI Market The competitive landscape of the market is strong with approved and off-label therapies. The market remains highly consolidated, with Pfizer, GlaxoSmithKline and Abbott remaining the leading competitors in the global AURI market. These players were the market leaders and are also expected to be the leaders for at least next seven years, as the pipeline has no first-in-class drugs that could further intensify the competition in the near future. Weak Pipeline with No Novel Therapies Will Cause a Market Share War in the AURI Market In the AURI therapeutics pipeline, there were four products in the late development stages in February 2011.

  3. There are three me-too products and one product extension, which will have little impact in the market. There is no emergence of promising agents with novel mechanisms of action, which would further intensify the competition. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Upper-Respiratory-Infections-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report GlobalData has released its new report, “Acute Upper Respiratory Infections (AURI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global AURI market. The report identifies the key trends shaping and driving the global AURI market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global AURI sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

  4. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Upper-Respiratory-Infections-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to 2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782

More Related